Remove Business Development Remove Clinical Development Remove Licensing
article thumbnail

Everest Medicines Announces Amended Agreement with Spero Therapeutics

The Pharma Data

The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory. SPR206 is in clinical development as an innovative option for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections. SHANGHAI , Jan. SHANGHAI , Jan.

article thumbnail

New €300m Angelini Ventures fund combines venture creation and direct investments to pave the way for healthcare transformation

pharmaphorum

Paolo is a life sciences executive with over 20 years of experience in venture capital, R&D, external innovation, and business development. Prior to joining Angelini Ventures, Thomas worked for Lundbeck as director of corporate business development and strategy.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer acquires Noria and PSMA Therapeutics to expand portfolio in prostate cancer

The Pharma Data

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Xofigo is currently under further evaluation in a broad clinical development program in prostate cancer and beyond.

article thumbnail

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g.

article thumbnail

LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)

The Pharma Data

According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. It may also allow for priority or rolling review of a company’s Biologics License Application (BLA).

article thumbnail

Aurobindo Pharma and COVAXX Sign an Exclusive Agreement to Develop and Commercialize COVID-19 Vaccine UB-612 for India and UNICEF

The Pharma Data

Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop, manufacture and sell COVAXX’s UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in other select emerging and developing markets. Aurobindo will manufacture the finished doses at its facilities in Hyderabad.

article thumbnail

Biopharma Money on the Move: December 2 – 8

The Pharma Data

Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and business development of potential new assets. Sigilon Therapeutics . Now live on the ticker, Sigilon hopes to sell 7 million shares for a $126 million raise.

RNA 52